A multicenter, retrospective analysis of patients with HR+, HER2− BC who received NAC was conducted, and an RWD was reported on patients’ clinical and pathological characteristics, treatments, and surgical and oncological outcomes in clinical practice. Here, HR is linked to breast cancer.